Office of the Director, National Institutes of Health; Notice of Meeting, 1108-1109 [2024-00247]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
1108
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–IL–08];
9. Japanese Patent No. 6742991 issued
August 19, 2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–JP–09];
10. Korean Patent No. 10–2445667 issued
September 16, 2022, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–KR–10];
11. Mexican Patent No. 375379 issued
September 25, 2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–MX–11];
12. Saudi Arabian Patent No. 7456 issued
January 5, 2021, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–SA–12];
13. United States Patent No. 10,174,098
issued January 8, 2019, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–US–13];
14. Hong Kong Patent No. HK1236203
issued January 8, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–HK–14];
15. United States Patent No. 10,870,687
issued December 22, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–US–15];
16. European Patent Application No.
19217074.4 filed December 17, 2019, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–EP–16];
17. Australian Patent No. 2019283892
issued May 13, 2021, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–AU–17];
18. Japanese Patent No. 6997267 issued
December 20, 2021, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–JP–53];
19. Saudi Arabian Patent Application No.
520412601 filed August 10, 2020, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–SA–54];
20. Hong Kong Patent Application No.
42020020661.3 filed November 24, 2020,
entitled ‘‘Anti-Human Papillomavirus 16 E7
T Cell Receptors’’ [HHS Reference No. E–
176–2014–0–HK–55];
21. Mexican Patent Application No. MX/a/
2020/010035 filed September 24, 2020,
entitled ‘‘Anti-Human Papillomavirus 16 E7
T Cell Receptors’’ [HHS Reference No. E–
176–2014–0–MX–56];
22. United States Patent No. 11,434,272
issued September 6, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–US–57];
23. Australian Patent No. 2021202227
issued February 23, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–AU–58];
24. Chinese Patent Application No.
20210399056.9 filed April 14, 2021, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–CN–59];
VerDate Sep<11>2014
16:38 Jan 08, 2024
Jkt 262001
25. Israeli Patent No. 282518 issued July 2,
2022, entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference No.
E–176–2014–0–IL–60];
26. Hong Kong Patent Application No.
42022046605.6 filed January 19, 2022,
entitled ‘‘Anti-Human Papillomavirus 16 E7
T Cell Receptors’’ [HHS Reference No. E–
176–2014–0–HK–62];
27. Japanese Patent No. 7291196 issued
June 6, 2023, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–JP–63];
28. Israeli Patent Application No. 290655
filed February 16, 2022, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–IL–64];
29. United States Patent Application No.
17/816,496 filed August 1, 2022, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–US–65];
30. Korean Patent Application No. 2022–
7032043 filed September 15, 2022, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–KR–66];
31. Australian Patent Application No.
2023200608 filed February 6, 2023, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–AU–01]; and
32. Japanese Patent Application No. 2023–
091878 filed June 2, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–JP–01].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Thermally controlled autologous T
cell therapy products for the treatment
of HPV-positive cancer in humans.’’
The E–176–2014 patent family is
primarily directed to an isolated TCR
reactive to HPV 16 E7 antigen in the
context of HLA–A*02:01 (the ‘‘E7
TCR’’). HPV describes a group of human
viruses known to cause malignancy. Of
the group, HPV–16 is the most prevalent
strain. Approximately 90% of adults are
estimated to have been exposed at some
point in their lifetime. HPV drives
transformation of infected cells through
the expression of certain oncoproteins,
chiefly E5, E6 and E7. The latter two are
constitutively expressed in malignant
cells and are necessary to maintain a
transformed state, rendering them
attractive therapeutic targets.
The E7 TCR may be useful in the
development of certain diagnostics and/
or therapeutics for the treatment of
cancers which express both the HPV 16
E7 oncoprotein and HLA–A*02:01.
Potential therapeutic applications of the
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
E7 TCR may include, but are not limited
to, engineered autologous or allogeneic
immune cell therapies (e.g., T cell or
natural killer cell-based) and TCR fusion
proteins and conjugates (e.g., soluble
TCR bi-specifics or TCR-drug
conjugates). The exclusive field of use
which may be granted to Port applies to
‘‘thermally controlled’’ autologous T
cell products, which is a subset of
engineered immune cell therapies.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: January 4, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–00209 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Council of Councils.
The meeting will be held as a virtual
meeting open to the public as indicated
below, with attendance limited to space
available. Individuals who plan to
attend as well as those who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, must notify the
Contact Person listed below in advance
of the meeting. The open session will be
E:\FR\FM\09JAN1.SGM
09JAN1
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov/).
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Council of Councils.
Date: January 25–26, 2024.
Open: January 25, 2024, 10:00 a.m. to 3:45
p.m.
Agenda: Welcome and Opening Remarks;
Announcements; NIH Program Updates;
Strategic Plans; and Other Business of the
Committee.
Place: National Institutes of Health,
Building 1, 1 Center Drive, Bethesda, MD
20892 (Virtual Meeting).
Closed: January 25, 2024, 4:00 p.m. to 5:00
p.m.
Agenda: Review of Grant Applications.
Place: National Institutes of Health,
Building 1, 1 Center Drive, Bethesda, MD
20892 (Virtual Meeting).
Open: January 26, 2024, 10:15 a.m. to 3:15
p.m.
Agenda: Strategic Plans; and Other
Business of the Committee.
Place: National Institutes of Health,
Building 1, 1 Center Drive, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Franziska Grieder, D.V.M.,
Ph.D., Executive Secretary, Council of
Councils, Director, Office of Research
Infrastructure Programs, Division of Program
Coordination, Planning, and Strategic
Initiatives, Office of the Director, NIH, 6701
Democracy Boulevard, Room 948, Bethesda,
MD 20892, GriederF@mail.nih.gov, 301–435–
0744.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Council of Council’s home page at https://
dpcpsi.nih.gov/council/ where an agenda
will be posted before the meeting date.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
VerDate Sep<11>2014
16:38 Jan 08, 2024
Jkt 262001
1109
Dated: January 4, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–00247 Filed 1–8–24; 8:45 am]
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings of the National
Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2024–1 Phase I: Development of a Serological
Test for Herpes Simplex Types 1 and 2
Infections (Topic 133).
Date: February 6, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Shilpakala Ketha, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F52A, Rockville, MD
20852, (301) 761–6821, shilpa.ketha@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Career Development
(Ks) and Conference support (R13) Review.
Date: February 22, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Dem II,
Suite 920, 6707 Democracy Boulevard,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Tianhong Wang, MD,
Ph.D., Scientific Review Officer, National
Institute of Biomedical Imaging and
Bioengineering, National Institutes of Health,
6707 Democracy Blvd., Bethesda, MD 20892,
(301) 435–1189, wangt3@mail.nih.gov.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 NCBIB Review
D–SEP.
Date: March 20–22, 2024.
Time: 9:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Dem II,
Suite 920, 6707 Democracy Blvd., Bethesda,
MD 20817 (Virtual Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Blvd., Suite 959, Bethesda, MD
20892, (301) 451–3398, hayesj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, National Institute of
Biomedical Imaging and Bioengineering,
National Institutes of Health.)
Dated: January 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: January 4, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00200 Filed 1–8–24; 8:45 am]
[FR Doc. 2024–00208 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\09JAN1.SGM
09JAN1
]]>Agencies
[Federal Register Volume 89, Number 6 (Tuesday, January 9, 2024)]
[Notices]
[Pages 1108-1109]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00247]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Council of
Councils.
The meeting will be held as a virtual meeting open to the public as
indicated below, with attendance limited to space available.
Individuals who plan to attend as well as those who need special
assistance, such as sign language interpretation or other reasonable
accommodations, must notify the Contact Person listed below in advance
of the meeting. The open session will be
[[Page 1109]]
videocast and can be accessed from the NIH Videocasting and Podcasting
website (https://videocast.nih.gov/).
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
title 5 U.S.C., as amended. The grant applications and/or contract
proposals and the discussions could disclose confidential trade secrets
or commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Council of Councils.
Date: January 25-26, 2024.
Open: January 25, 2024, 10:00 a.m. to 3:45 p.m.
Agenda: Welcome and Opening Remarks; Announcements; NIH Program
Updates; Strategic Plans; and Other Business of the Committee.
Place: National Institutes of Health, Building 1, 1 Center
Drive, Bethesda, MD 20892 (Virtual Meeting).
Closed: January 25, 2024, 4:00 p.m. to 5:00 p.m.
Agenda: Review of Grant Applications.
Place: National Institutes of Health, Building 1, 1 Center
Drive, Bethesda, MD 20892 (Virtual Meeting).
Open: January 26, 2024, 10:15 a.m. to 3:15 p.m.
Agenda: Strategic Plans; and Other Business of the Committee.
Place: National Institutes of Health, Building 1, 1 Center
Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Franziska Grieder, D.V.M., Ph.D., Executive
Secretary, Council of Councils, Director, Office of Research
Infrastructure Programs, Division of Program Coordination, Planning,
and Strategic Initiatives, Office of the Director, NIH, 6701
Democracy Boulevard, Room 948, Bethesda, MD 20892,
[email protected], 301-435-0744.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Council of Council's home
page at https://dpcpsi.nih.gov/council/ where an agenda will be
posted before the meeting date.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: January 4, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-00247 Filed 1-8-24; 8:45 am]
BILLING CODE 4140-01-P
